# IQVIA **Source:** https://geo.sig.ai/brands/iqvia **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** iqvia.com **Last Updated:** 2026-04-14 ## Summary World's largest CRO and healthcare data company; $15.2B FY2024 revenue; 1B+ patient records; powers pharma R&D and commercial analytics; benefits from GLP-1 and oncology pipeline boom. ## Company Overview IQVIA Holdings is the world's largest contract research organization (CRO) and leading provider of healthcare data and analytics, formed in 2016 through the $9 billion merger of IMS Health (healthcare information and technology services) and Quintiles Transnational Holdings (clinical research services), headquartered in Durham, North Carolina and trading on NYSE (IQV). The company generated approximately $15.2 billion in revenues for FY2024 under CEO Ari Bousbib, who led both legacy companies and has driven the combined entity to become an indispensable partner to pharmaceutical and biotechnology companies across the drug development lifecycle—from clinical trial design and execution through regulatory approval and commercial launch analytics. IQVIA's unique competitive moat is its healthcare data ecosystem: the company aggregates and manages one of the world's largest collections of real-world evidence, including de-identified patient-level claims data, electronic health records, prescription dispensing data, and hospital utilization records covering over 1 billion patient records globally. This proprietary data infrastructure powers market research and commercial analytics for pharma customers tracking drug sales performance, competitor market share, prescription trends, and treatment pathway optimization. The Technology & Analytics Solutions (TAS) segment provides this data platform alongside software and managed services, while the Research & Development Solutions (RDS) segment manages clinical trials from Phase I through Phase IV using IQVIA's global clinical infrastructure of 90,000+ investigators and 7,000 technology applications. In 2025-2026, IQVIA benefits from record levels of pharmaceutical R&D investment—driven by the GLP-1 obesity drug boom (Novo Nordisk, Eli Lilly), oncology pipeline expansion, and mRNA technology applications beyond COVID—as drug developers require both CRO capacity and real-world evidence to support regulatory submissions and commercial strategies. The CRO industry consolidation has left IQVIA competing primarily with ICON plc (merged with PRA Health Sciences), Syneos Health (acquired by private equity in 2023), and Covance (LabCorp CDS division), with smaller niche CROs filling specialized indications. AI-driven clinical trial optimization—applying machine learning to site selection, patient recruitment, and protocol design—is a key differentiator that IQVIA's data scale uniquely enables, potentially compressing trial timelines and improving success rates for pharmaceutical clients. ## Frequently Asked Questions ### What does IQVIA do? IQVIA is a global leader in healthcare information technology and clinical research services that helps pharmaceutical, biotechnology, and medical device companies accelerate innovation. The company combines the world's largest healthcare data repository (over 1.2 billion patient records), advanced analytics and AI capabilities, and comprehensive clinical research services to support the entire therapeutic lifecycle from drug development through commercialization. IQVIA operates three main business segments: Technology & Analytics Solutions (40% of revenue), Research & Development Solutions (55%), and Contract Sales & Medical Solutions (5%). ### Who are IQVIA's customers and target market? IQVIA serves over 220,000 customers globally, primarily in the life sciences and healthcare industries. Key customer segments include pharmaceutical companies (both large multinational corporations and emerging biotech firms), medical device manufacturers, healthcare payers and providers, government health agencies, and academic research institutions. The company's solutions address needs across the therapeutic lifecycle, from early-stage research and clinical trials through regulatory approval, commercial launch, and post-market surveillance. ### When was IQVIA founded? IQVIA was formed in 2016 through the merger of two healthcare industry pioneers: IMS Health (founded in 1954 as Intercontinental Marketing Services) and Quintiles (founded in 1982 by Dennis Gillings). The merger was announced in May 2016, completed in October 2016, and the company adopted the IQVIA name on November 6, 2017. The combined entity brought together IMS Health's 60+ year legacy in healthcare data and analytics with Quintiles' pioneering work in contract research services. ### Where is IQVIA based? IQVIA is headquartered in Durham, North Carolina, USA. The company operates globally with approximately 88,000 employees across more than 100 countries in North America, Europe, Latin America, Asia Pacific, and other regions. This extensive global footprint enables IQVIA to support multinational clinical trials and provide localized expertise in diverse healthcare markets worldwide. ### How much funding has IQVIA raised? IQVIA is a publicly-traded company (NYSE: IQV) and does not raise venture capital funding. The company was formed through a $17.6 billion merger of IMS Health and Quintiles in 2016. Both predecessor companies had significant private equity backing before the merger: IMS Health was acquired by TPG Capital and partners for $5.2 billion in 2010, while Quintiles was taken private for $3.9 billion in 2013. IQVIA now has a market capitalization of approximately $39.4 billion as of 2024. ### What makes IQVIA different from competitors? IQVIA's unique competitive advantage stems from its unmatched combination of assets and capabilities. The company maintains the healthcare industry's largest data repository with over 1.2 billion de-identified patient health records, providing comprehensive insights into patient healthcare journeys. This is combined with advanced AI and analytics capabilities (including the award-winning IQVIA AI Assistant), end-to-end clinical research services with a global site network, and deep therapeutic and regulatory expertise. Unlike pure-play CROs or data vendors, IQVIA offers integrated solutions spanning the entire therapeutic lifecycle from R&D through commercialization, backed by decades of domain expertise and proprietary technology platforms. ### Who are IQVIA's main competitors? In clinical research services, IQVIA competes with CROs including Syneos Health, Covance (LabCorp), Parexel, ICON plc, and PRA Health Sciences. In healthcare analytics and technology, competitors include Optum (holds 23.69% health analytics market share vs. IQVIA's 33.02%), Medidata Solutions (now part of Dassault Systèmes), and IBM Watson Health. IQVIA also faces indirect competition from consulting firms like McKinsey, Accenture, and Cognizant, and laboratory testing firms like WuXi AppTec. However, few competitors offer IQVIA's breadth of integrated capabilities spanning both clinical research and healthcare analytics. ### How can I contact IQVIA? IQVIA can be contacted through their main website at www.iqvia.com, which provides contact forms for sales inquiries, partnership opportunities, and general questions. The company's headquarters is located in Durham, North Carolina. For investor relations, visit investors.iqvia.com. For career opportunities, visit jobs.iqvia.com. IQVIA also maintains regional offices and contact points in over 100 countries to serve local markets. ### Is IQVIA hiring? Yes, IQVIA actively recruits talent across its global operations with 88,000+ employees. The company seeks professionals in clinical research, data science, analytics, software engineering, healthcare consulting, regulatory affairs, and other specialized roles. IQVIA offers competitive compensation, comprehensive benefits including 12 weeks maternity leave, flexible work arrangements, tuition reimbursement, personalized career coaching, and professional development opportunities. Career opportunities can be explored at jobs.iqvia.com, with positions available across over 100 countries. ### What's the latest news about IQVIA? Recent major announcements include: (1) January 2025 partnership with NVIDIA to develop healthcare-grade AI models and agentic AI agents; (2) February 2025 reporting of record full-year 2024 results with $15.4 billion revenue and $3.68 billion adjusted EBITDA, plus $2 billion increase in share repurchase authorization; (3) Award-winning IQVIA AI Assistant launched in September 2024, winning the PM360 Innovation Award for Artificial Intelligence in February 2025; (4) April 2024 expanded partnership with Salesforce to accelerate Life Sciences Cloud development; (5) August 2025 collaborations with Flagship Pioneering and Veeva Systems announced. ### What is IQVIA's market position? IQVIA is the global leader in healthcare analytics and one of the world's largest contract research organizations. The company holds a dominant 33.02% market share in the health analytics sector, significantly ahead of competitors like Optum (23.69%) and Medidata (18.81%). As a Fortune 500 and S&P 500 company with $15.4 billion in annual revenue and $39.4 billion market capitalization, IQVIA serves as a mission-critical partner to the life sciences industry. The company's R&DS segment maintains a contracted backlog of $31.1 billion, demonstrating strong long-term client relationships and revenue visibility. ### What are IQVIA's future plans? IQVIA's strategic priorities focus on advancing AI and automation capabilities through the NVIDIA partnership to build healthcare-grade foundation models and agentic AI agents, expanding real-world evidence solutions to meet growing regulatory and payer demands, growing the Data Centers business segment which showed 25% revenue growth in 2024, enhancing decentralized and hybrid trial capabilities to improve patient access and trial efficiency, and continuing to integrate acquired capabilities in ITAD services and specialized analytics. For 2025, the company has issued guidance of $15.7-$16.1 billion revenue, $3.77-$3.89 billion adjusted EBITDA, and $11.70-$12.10 adjusted diluted EPS, reflecting continued strong growth. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*